Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Trial Profile

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs Ingenol disoxate (Primary)
  • Indications Actinic keratosis
  • Focus Therapeutic Use
  • Sponsors LEO Pharma
  • Most Recent Events

    • 22 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 26 Jan 2016 New source identified and integrated (European Clinical Trials Database EudraCT2015-002452-27).
    • 11 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top